Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cloxacillin is a semisynthetic penicillin antibiotic used primarily to treat infections caused by beta-hemolytic streptococci, pneumococci, and staphylococci—including those that produce beta-lactamase. It is a chlorinated derivative of oxacillin and belongs to the class of penicillinase-resistant penicillins. Cloxacillin works by binding to specific penicillin-binding proteins (PBPs) inside the bacterial cell wall, thereby inhibiting the final stage of bacterial cell wall synthesis. This leads to cell lysis mediated by autolytic enzymes such as autolysins[1][5][8]. It is effective against gram-positive organisms, especially *Staphylococcus aureus*[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cloxacillin.